Chlamydia Diagnostics Market Analysis and Opportunity Assessment 2023 to 2033

The global Chlamydia Diagnostics market revenue is expected to reach US$ 3.69 billion by 2033. The market's expansion could be attributed to growing awareness of the importance of STI testing.

The Chlamydia Diagnostics market in Europe is expected to grow rapidly in the next years due to a variety of causes. The increased prevalence of chlamydia in the region is one of the key market reasons. According to a study conducted by the European Centre for Disease Prevention and Control, the number of reported chlamydia infections in Europe has steadily climbed over the last decade, with over 410,000 cases reported in 2019. The demand for Chlamydia Diagnostics in the region is expected to rise as the prevalence of chlamydia rises.

The availability of enhanced diagnostic tests is another major reason driving the growth of the Chlamydia Diagnostics market. Because of their high sensitivity and specificity, nucleic acid amplification tests (NAATs) are the most often utilised chlamydia diagnostic tests.

Furthermore, because these tests can detect bacterial DNA in a patient's urine, swab, or blood sample, they provide patients with a handy and non-invasive option. Rapid diagnostic technologies, such as the Alere i platform and the Roche Cobas Liat System, have also been developed in recent years, enabling for rapid and accurate chlamydia detection.

Key Takeaways from the Market Study

  • NAATs are expected to account for 49% of the Chlamydia Diagnostics market in 2023.
  • The global Chlamydia Diagnostics market is expected to grow at an 11% CAGR between 2023 and 2033.
  • North America is expected to represent 48% of the Chlamydia Diagnostics market in 2023.
  • The European Chlamydia Diagnostics market is expected to account for 46% of the total by 2023.

Competitive Landscape

Key players in the Chlamydia Diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA Becton, Dickinson and Company, Bio-Rad Laboratories, Pfizer, Inc., AstraZeneca and Teva Pharmaceuticals

Read More@ https://www.futuremarketinsights.com/reports/chlamydia-diagnostics-market

Key Segments Profiled in the Chlamydia Diagnostics Industry Survey

Test Type:

  • Culture Tests
  • Nucleic Acid Amplification Tests (NAAT)
  • Direct Fluorescent Antibody Tests
  • Serology Tests

End User:

  • Hospitals
  • Clinics
  • Diagnostic Centres

Comments

Post a Comment

Popular posts from this blog

Handheld Ultrasound Scanners Market Will Generate Booming Growth Opportunities to 2032

Image
According to industry predictions, the global Handheld Ultrasound Scanners Market Demand will increase at a CAGR of 9.1% from 2022 to 2032, reaching a value of US$ 472.1 million by the end of 2022. By 2032, sales are estimated to exceed a valuation of roughly US$ 1.1 billion. With an expected 83.6% market share in 2021, the wired modality now leads the sector. Because they connect to Bluetooth or Wi-Fi devices such as mobile phones or tablets, Handheld Ultrasound Scanners are gaining appeal among both medical professionals and non-radiologists. These devices improve networking systems and ease picture transfer to medical facilities. Global Handheld Ultrasound Scanners Market: Dynamics         Technological advancements in medical imaging devices, increased use of Handheld Ultrasound Scanners among non-radiologists, benefits from international trade agreements, increased importing of imaging diagnostics systems, increased use of Handheld Ultrasound Scanners in emergency medical service
Read more

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

Antidiabetics Market to reach US$ 223 billion by 2032, growing at a 9.6% CAGR from 2022 to 2032 | Future Market Insights, Inc.

Image
The global Antidiabetics Market is expected to earn US$ 223 billion while expanding at a CAGR of 9.6% during the forecast period. The rising prevalence of diabetes worldwide can be attributed to the market's expansion. The ageing baby boomer population is another factor driving the market during the forecast period. According to the International Diabetes Federation, the global diabetes incidence will increase from 366 million in 2011 to 552 million by 2030. During the forecast period, the industry is expected to benefit from a significant increase in the number of diabetic patients. Furthermore, new product development is expected to benefit the market in the near future. For example, Novo Nordisk, a Danish pharmaceutical company, announced the launch of oral semaglutide for the treatment of Type 2 diabetes in India in January 2022. Furthermore, the development of advanced pumps based on smart technologies like AI and ML is expected to open up a slew of new doors. For exampl
Read more